Dehydroepiandrosterone (DHEA) Intervention To Treat Ovarian Aging
Launched by UNIVERSITY OF NOTTINGHAM · Apr 4, 2012
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
The purpose of this study is to evaluate the role of DHEA in counteracting the effects of ovarian ageing in an in-vitro fertilization (IVF) model. The study will examine whether the use of DHEA could improve clinical pregnancy rates following IVF treatment in women predicted to have aged ovaries by increasing oocyte quantity (ovarian response to gonadotrophins) and/ or by improving oocyte quality. The oocyte quality will be assessed by morphological and molecular markers.
This study will provide a mechanistic framework for translational research on mechanisms of ovarian ageing and drug int...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged above 23 years with diminished ovarian reserve (predicted to be poor-responder), defined as antral follicle count \<10 and/or Anti-Mullerian hormone \<5pmol/L
- • Women undergoing IVF and IVF/ICSI treatment
- • Women must have a regular spontaneous menstrual cycle of 21 - 35 days
- Exclusion Criteria:
- • Women with BMI \>35 Kg/M2
- • Women with a single ovary
- • Women with untreated hydrosalpinx/ submucous fibroid/ endometrial polyp at the start of treatment
- • Women with any history of seizure disorders
- • Women with previous participation in this trial in an earlier treatment cycle
- • Women with any known endocrine disorders such as congenital adrenal hyperplasia, thyroid diseases, hyperprolactinemia
- • Known allergy to DHEA
- • Diabetic women on insulin as insulin lowers DHEA levels and might reduce the effectiveness of DHEA supplements.
About University Of Nottingham
The University of Nottingham is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses cutting-edge research and expert faculty to address pressing medical challenges. Through its dedicated clinical trials unit, the University of Nottingham conducts rigorous studies aimed at improving patient outcomes and contributing to the global body of medical knowledge. The institution prioritizes ethical practices and participant safety, ensuring that all trials are designed to uphold the highest standards of scientific integrity and regulatory compliance.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, Nottinghamshire, United Kingdom
Patients applied
Trial Officials
Kannamannadiar Jayaprakasan, MRCOG,PhD.
Principal Investigator
Division of Obstetrics and Gynaecology, School of Clinical Sciences, University of Nottingham
Bruce Campbell, PhD, DSc
Study Director
University of Nottingham
Nick Raine-Fenning, MRCOG, PhD
Study Director
University of Nottingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials